CELU|Celularity Inc|Price:1.300|Chg%:0.13

More Details of Celularity Inc Company

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

Celularity Inc Info



Ticker SymbolCELU

Company nameCelularity Inc

IPO dateMay 23, 2019

CEOHariri (Robert J)

Number of employees123

Security typeOrdinary Share

Fiscal year-endMay 23

Address170 Park Ave

CityFLORHAM PARK

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code07932

Phone19087682170

Websitehttps://celularity.com/

Ticker SymbolCELU

IPO dateMay 23, 2019

CEOHariri (Robert J)

Company Executives of Celularity Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Robert J. (Bob) Hariri, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

2.86M

+3281.00%

Mr. Vincent Levien

Independent Director

157.55K

+28847.00%

Dr. Peter H. Diamandis, M.D.

Independent Director

--

Ms. Diane L. Parks

Independent Director

--

Mr. Stephen A. Brigido

President - Degenerative Disease

--

Mr. John R. Haines

Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary

--

Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.

Independent Director

--

Mr. Carlos Ramirez

Senior Vice President - Investor Relations

--

Mr. Joseph Dossantos

Interim Chief Financial Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. Robert J. (Bob) Hariri, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

2.86M

+3281.00%

Mr. Vincent Levien

Independent Director

157.55K

+28847.00%

Dr. Peter H. Diamandis, M.D.

Independent Director

--

Ms. Diane L. Parks

Independent Director

--

Mr. Stephen A. Brigido

President - Degenerative Disease

--

Mr. John R. Haines

Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sat, Jan 3

Shareholders

Shareholder Types

Shareholders

Proportion

Genting Bhd

21.97%

Hariri (Robert J)

9.91%

Starr International Company, Inc.

5.30%

Lincoln Alternative Strategies LLC

4.27%

C.V. Starr & Co., Inc.

2.65%

Other

55.90%

Shareholders

Proportion

Genting Bhd

21.97%

Hariri (Robert J)

9.91%

Starr International Company, Inc.

5.30%

Lincoln Alternative Strategies LLC

4.27%

C.V. Starr & Co., Inc.

2.65%

Other

55.90%

Shareholder Types

Shareholders

Proportion

Corporation

26.24%

Individual Investor

15.43%

Investment Advisor

8.72%

Insurance Company

2.65%

Investment Advisor/Hedge Fund

1.30%

Hedge Fund

0.38%

Research Firm

0.17%

Family Office

0.04%

Other

45.07%

Institutional Shareholding



Updated: Mon, Dec 8

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

71

3.82M

13.73%

--

2025Q3

80

3.82M

16.36%

+119.97K

2025Q2

92

3.70M

17.46%

+189.07K

2025Q1

120

3.51M

18.18%

-579.52K

2024Q4

135

3.39M

17.70%

+120.20K

2024Q3

149

3.27M

18.60%

+20.75K

2024Q2

160

3.32M

18.56%

+109.90K

2024Q1

166

3.20M

18.29%

-780.71K

2023Q4

164

3.20M

20.76%

-511.70K

2023Q3

164

3.71M

20.21%

+96.25K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Genting Bhd

6.34M

22.25%

--

Oct 30, 2025

Hariri (Robert J)

2.86M

10.04%

+3.28K

+0.11%

Oct 30, 2025

Starr International Company, Inc.

1.53M

5.37%

--

Oct 30, 2025

Lincoln Alternative Strategies LLC

1.23M

4.32%

+1.23M

--

Jul 14, 2025

C.V. Starr & Co., Inc.

764.07K

2.68%

--

Sep 30, 2025

The Vanguard Group, Inc.

676.65K

2.38%

+176.52K

+35.29%

Sep 30, 2025

Ling (Geoffrey M. D.)

472.29K

1.66%

+192.42K

+68.75%

Dec 29, 2025

Diamandis (Peter)

441.18K

1.55%

+192.42K

+77.35%

Dec 29, 2025

Parks (Diane L.)

344.98K

1.21%

+192.42K

+126.12%

Dec 29, 2025

Levien (Vincent)

128.70K

0.45%

+125.00K

+3379.29%

Dec 29, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares Micro-Cap ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

0%

iShares Micro-Cap ETF

Proportion0%

DFA Dimensional US Sustainability Core 1 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Date

Ex-dividend Date

Type

Ratio

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1